Yale Cancer Center-Advanced Training Program for Physician-Scientists (YCC-ATPP)

Dr. Roy Herbst is internationally recognized as one of the foremost leaders in the development of targeted and immune-based therapies for the treatment of lung cancer. His pioneering clinical studies investigating epidermal growth factor receptor (EGFR)-targeted agents in lung and head and neck cancers brought forth a new era in precision medicine and oncology. His translational research spurred the evolution of adaptive clinical trial design toward increasingly more personalized therapeutic approaches, and he was among the first to champion the use of targeted therapies during the earliest stages of disease. His groundbreaking studies have identified critical biomarkers of sensitivity and resistance to immunotherapy, helping to inform treatment decision-making. His work throughout the past three decades has significantly advanced the standard of care for patients with lung cancer, greatly enhancing survival and quality of life beyond what was previously thought to be possible. After earning B.S. and M.S. degrees from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in Molecular Cell Biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in Medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in Medicine Oncology and Hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed an M.S. degree in Clinical Translational Research at Harvard University in Cambridge, Massachusetts. Prior to his appointment at Yale, Dr. Herbst was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology, at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He also served as Professor in the Department of Cancer Biology and Co-Director of the Phase I Clinical Trials Program. Dr. Herbst traversed to the forefront of personalized medicine and immunotherapy early in his career, identifying key biomarkers and bringing novel targeted and immune-based treatments to patients by serving as principal investigator (PI) for seminal clinical trials testing these agents in advanced-stage lung cancers. This work led to the approval of several important targeted therapies (such as gefitinib, erlotinib, cetuximab, bevacizumab, and axitinib), that revolutionized the field and quickly became the standard of care. This research laid the groundwork for more recent paradigm-shifting studies led by Dr. Herbst investigating targeted agents in earlier stages of disease. One such study, the ADAURA trial, demonstrated the dramatic effect of the third generation EGFR-inhibitor osimertinib as an adjuvant therapy in early-stage resected non-small cell lung cancer, the results of which were published twice in the New England Journal of Medicine, and led to worldwide drug approval and expanded access for patients. He and his colleagues at Yale were also among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer clinical trials of the PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. Dr. Herbst’s leadership in this arena has been formally recognized by his selection to deliver plenary presentations at the American Society of Clinical Oncology (ASCO) annual meetings in 2020 and 2023. Dr. Herbst’s work on umbrella trials, master protocols, and pragmatic trials has further galvanized the field of targeted therapy and cancer drug approvals by the United States (US) Food and Drug Administration (FDA). Nationally, he works closely with public-private partnerships to develop large master protocol clinical studies. He was co-leader of the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination-1 (BATTLE-1) and subsequent BATTLE-2 clinical trial programs and was the founding PI of the Lung Master Protocol (Lung-MAP), a position he held for ten years. The Lung-MAP protocol utilizes patient biomarkers to choose treatments that are most likely to provide benefit. He testified on this before the US House of Representatives 21st Century Cures Committee and has helped solidify master protocols as the preferred clinical trial design by the FDA. He is currently the Chair Emeritus and Senior Advisor for the Lung-MAP trial through SWOG. Extending on the success of the Lung-MAP initiative, Dr. Herbst was instrumental in the design and implementation of the Pragmatica-Lung Cancer trial, modernizing and simplifying inclusion criteria to expand access to life-saving treatments to those patients who need it most, often from underserved and rural areas. As a testament to the efficiency of such a trial design, it has accrued 800 patients nationwide in just one year. Dr. Herbst is a highly respected clinician­ scientist who has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer for the journal Nature that is widely cited. He has authored or co-authored more than 500 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum. His abstracts have been presented at the annual meetings of ASCO, the American Association for Cancer Research (AACR), the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), and the European Organization for Research and Treatment of Cancer, to name a few. In 2015, and again in 2020 and 2025, Dr. Herbst’s team at Yale was awarded a Lung Cancer SPORE (P50 grant) by the National Cancer Institute (NCI), which has identified new immunotherapies and mechanisms of sensitivity and resistance to EGFR targeted therapies. In 2017, he successfully helped establish and led the Yale-AstraZeneca Alliance, a strategic partnership that leverages the strengths of academia and industry working together to generate breakthroughs in cancer treatment and care. His work has also been funded by ASCO, AACR, the US Department of Defense, and by an AACR/Stand Up to Cancer Dream Team grant. Dr. Herbst is a Fellow of ASCO and a member of AACR, where he serves as Chair of the AACR Science Policy and Government Affairs Committee. He has been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings. He has served on both the IASLC and AACR Board of Directors. He is a Fellow of the American College of Physicians and an elected member of the Association of American Physicians. He has served over ten years in non-consecutive terms as a member of the National Academy of Medicine’s (NAM’s) Cancer Policy Forum, now on his second term, for which he organized and chaired or co-chaired several meetings focused on policy issues in personalized medicine and tobacco control such as, “Policy Issues in the Development of Personalized Medicine in Oncology,” “Reducing Tobacco Related Cancer Incidence and Mortality,” “Optimizing Public-Private Partnerships (PPP) for Clinical Research,” and “Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes.” Most recently he led the authorship of the manuscript from the 2023 PPP meeting published in the Journal of the National Cancer Institute and is leading the writing team for the most recent workshop. For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the IASLC at their 17th WCLC in Vienna, Austria. He and his team at the Yale Cancer Center were awarded the 2018 Team Science Award from the Association for Clinical and Translational Science for their pioneering work in advancing our understanding of immunotherapy. In 2020, Dr. Herbst was awarded the AACR Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy. Dr. Herbst is the recipient of the 2022 Giants of Cancer Care® award for Lung Cancer and was honored by Friends of Cancer Research in 2021 as one of their 25 scientific and advocacy leaders who, through their work and partnership, have been instrumental over the course of the last 25 years in making significant advancements for patients. In 2024, Dr. Herbst became a member of the Board of Directors for Friends of Cancer Research. That year, he was also awarded the Ezra Greenspan Award from the Chemotherapy+ Foundation. In 2025, he was elected into the Connecticut Academy of Science and Engineering. Beyond Dr. Herbst’s exceptional research accomplishments, he remains a noted educator and teacher. Dr. Herbst is proud to serve as the creator and inaugural director of the Masters in Health Science in Clinical Investigation at the Yale Medical School, which provides training in, and integration of, translational research of all types. He has written chapters for major oncology textbooks (Devita, Frei) and is the Hematology/Oncology Section Editor for the upcoming 28th Edition of Goldman-Cecil Medicine. Since 2021, he has been the Co-Chair/Co-Director of the Robert A. Winn Excellence in Clinical Trials Award Program: Design and Implementation of Clinical Trials Workshop in collaboration with the AACR. Today, and throughout Dr. Herbst’s storied career, he has remained steadfastly committed to delivering exceptional and compassionate patient care, producing top-notch translational research, and providing enlightening educational experiences to trainees that will prepare them for successful and meaningful careers as healthcare providers and clinical researchers. He has and continues to promote an atmosphere of collegiality and collaboration, building translational bridges between basic and clinical researchers, as well as between academic and industry partners. Dr. Herbst inspires his peers, colleagues, and trainees to strive for excellence in the laboratory, clinic, classroom, and community, and his legacy will make an impact on patients for years to come.

Lieping Chen, MD, PhD, is an immunologist and physician-scientist. His research focuses on basic T cell biology and the translation of laboratory discoveries into clinical therapies, with a primary emphasis on cancer immunotherapy. Dr. Chen’s laboratory is renowned for the 1999 discovery of the B7-H1 (PD-L1) molecule and the subsequent identification of the PD-1/PD-L1 pathway as a critical mechanism of immune evasion in the tumor microenvironment. This breakthrough, hailed as the #1 Breakthrough of the Year by Science magazine in 2013, led to the development of anti-PD-1/PD-L1 antibodies, which are now global standards of care for a broad spectrum of advanced cancers. A prolific investigator with over 400 peer-reviewed publications, Dr. Chen held faculty positions at the Mayo Clinic, Johns Hopkins University, and scientist positions in the Bristol-Myers Squibb Co. before joining Yale University. He is a member of the National Academy of Sciences, the National Academy of Medicine, and a Fellow of the American Association for Cancer Research (AACR).

Dr. Roy Herbst is internationally recognized as one of the foremost leaders in the development of targeted and immune-based therapies for the treatment of lung cancer. His pioneering clinical studies investigating epidermal growth factor receptor (EGFR)-targeted agents in lung and head and neck cancers brought forth a new era in precision medicine and oncology. His translational research spurred the evolution of adaptive clinical trial design toward increasingly more personalized therapeutic approaches, and he was among the first to champion the use of targeted therapies during the earliest stages of disease. His groundbreaking studies have identified critical biomarkers of sensitivity and resistance to immunotherapy, helping to inform treatment decision-making. His work throughout the past three decades has significantly advanced the standard of care for patients with lung cancer, greatly enhancing survival and quality of life beyond what was previously thought to be possible. After earning B.S. and M.S. degrees from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in Molecular Cell Biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in Medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in Medicine Oncology and Hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed an M.S. degree in Clinical Translational Research at Harvard University in Cambridge, Massachusetts. Prior to his appointment at Yale, Dr. Herbst was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology, at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He also served as Professor in the Department of Cancer Biology and Co-Director of the Phase I Clinical Trials Program. Dr. Herbst traversed to the forefront of personalized medicine and immunotherapy early in his career, identifying key biomarkers and bringing novel targeted and immune-based treatments to patients by serving as principal investigator (PI) for seminal clinical trials testing these agents in advanced-stage lung cancers. This work led to the approval of several important targeted therapies (such as gefitinib, erlotinib, cetuximab, bevacizumab, and axitinib), that revolutionized the field and quickly became the standard of care. This research laid the groundwork for more recent paradigm-shifting studies led by Dr. Herbst investigating targeted agents in earlier stages of disease. One such study, the ADAURA trial, demonstrated the dramatic effect of the third generation EGFR-inhibitor osimertinib as an adjuvant therapy in early-stage resected non-small cell lung cancer, the results of which were published twice in the New England Journal of Medicine, and led to worldwide drug approval and expanded access for patients. He and his colleagues at Yale were also among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer clinical trials of the PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. Dr. Herbst’s leadership in this arena has been formally recognized by his selection to deliver plenary presentations at the American Society of Clinical Oncology (ASCO) annual meetings in 2020 and 2023. Dr. Herbst’s work on umbrella trials, master protocols, and pragmatic trials has further galvanized the field of targeted therapy and cancer drug approvals by the United States (US) Food and Drug Administration (FDA). Nationally, he works closely with public-private partnerships to develop large master protocol clinical studies. He was co-leader of the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination-1 (BATTLE-1) and subsequent BATTLE-2 clinical trial programs and was the founding PI of the Lung Master Protocol (Lung-MAP), a position he held for ten years. The Lung-MAP protocol utilizes patient biomarkers to choose treatments that are most likely to provide benefit. He testified on this before the US House of Representatives 21st Century Cures Committee and has helped solidify master protocols as the preferred clinical trial design by the FDA. He is currently the Chair Emeritus and Senior Advisor for the Lung-MAP trial through SWOG. Extending on the success of the Lung-MAP initiative, Dr. Herbst was instrumental in the design and implementation of the Pragmatica-Lung Cancer trial, modernizing and simplifying inclusion criteria to expand access to life-saving treatments to those patients who need it most, often from underserved and rural areas. As a testament to the efficiency of such a trial design, it has accrued 800 patients nationwide in just one year. Dr. Herbst is a highly respected clinician­ scientist who has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer for the journal Nature that is widely cited. He has authored or co-authored more than 500 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum. His abstracts have been presented at the annual meetings of ASCO, the American Association for Cancer Research (AACR), the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), and the European Organization for Research and Treatment of Cancer, to name a few. In 2015, and again in 2020 and 2025, Dr. Herbst’s team at Yale was awarded a Lung Cancer SPORE (P50 grant) by the National Cancer Institute (NCI), which has identified new immunotherapies and mechanisms of sensitivity and resistance to EGFR targeted therapies. In 2017, he successfully helped establish and led the Yale-AstraZeneca Alliance, a strategic partnership that leverages the strengths of academia and industry working together to generate breakthroughs in cancer treatment and care. His work has also been funded by ASCO, AACR, the US Department of Defense, and by an AACR/Stand Up to Cancer Dream Team grant. Dr. Herbst is a Fellow of ASCO and a member of AACR, where he serves as Chair of the AACR Science Policy and Government Affairs Committee. He has been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings. He has served on both the IASLC and AACR Board of Directors. He is a Fellow of the American College of Physicians and an elected member of the Association of American Physicians. He has served over ten years in non-consecutive terms as a member of the National Academy of Medicine’s (NAM’s) Cancer Policy Forum, now on his second term, for which he organized and chaired or co-chaired several meetings focused on policy issues in personalized medicine and tobacco control such as, “Policy Issues in the Development of Personalized Medicine in Oncology,” “Reducing Tobacco Related Cancer Incidence and Mortality,” “Optimizing Public-Private Partnerships (PPP) for Clinical Research,” and “Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes.” Most recently he led the authorship of the manuscript from the 2023 PPP meeting published in the Journal of the National Cancer Institute and is leading the writing team for the most recent workshop. For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the IASLC at their 17th WCLC in Vienna, Austria. He and his team at the Yale Cancer Center were awarded the 2018 Team Science Award from the Association for Clinical and Translational Science for their pioneering work in advancing our understanding of immunotherapy. In 2020, Dr. Herbst was awarded the AACR Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy. Dr. Herbst is the recipient of the 2022 Giants of Cancer Care® award for Lung Cancer and was honored by Friends of Cancer Research in 2021 as one of their 25 scientific and advocacy leaders who, through their work and partnership, have been instrumental over the course of the last 25 years in making significant advancements for patients. In 2024, Dr. Herbst became a member of the Board of Directors for Friends of Cancer Research. That year, he was also awarded the Ezra Greenspan Award from the Chemotherapy+ Foundation. In 2025, he was elected into the Connecticut Academy of Science and Engineering. Beyond Dr. Herbst’s exceptional research accomplishments, he remains a noted educator and teacher. Dr. Herbst is proud to serve as the creator and inaugural director of the Masters in Health Science in Clinical Investigation at the Yale Medical School, which provides training in, and integration of, translational research of all types. He has written chapters for major oncology textbooks (Devita, Frei) and is the Hematology/Oncology Section Editor for the upcoming 28th Edition of Goldman-Cecil Medicine. Since 2021, he has been the Co-Chair/Co-Director of the Robert A. Winn Excellence in Clinical Trials Award Program: Design and Implementation of Clinical Trials Workshop in collaboration with the AACR. Today, and throughout Dr. Herbst’s storied career, he has remained steadfastly committed to delivering exceptional and compassionate patient care, producing top-notch translational research, and providing enlightening educational experiences to trainees that will prepare them for successful and meaningful careers as healthcare providers and clinical researchers. He has and continues to promote an atmosphere of collegiality and collaboration, building translational bridges between basic and clinical researchers, as well as between academic and industry partners. Dr. Herbst inspires his peers, colleagues, and trainees to strive for excellence in the laboratory, clinic, classroom, and community, and his legacy will make an impact on patients for years to come.

Lieping Chen, MD, PhD, is an immunologist and physician-scientist. His research focuses on basic T cell biology and the translation of laboratory discoveries into clinical therapies, with a primary emphasis on cancer immunotherapy. Dr. Chen’s laboratory is renowned for the 1999 discovery of the B7-H1 (PD-L1) molecule and the subsequent identification of the PD-1/PD-L1 pathway as a critical mechanism of immune evasion in the tumor microenvironment. This breakthrough, hailed as the #1 Breakthrough of the Year by Science magazine in 2013, led to the development of anti-PD-1/PD-L1 antibodies, which are now global standards of care for a broad spectrum of advanced cancers. A prolific investigator with over 400 peer-reviewed publications, Dr. Chen held faculty positions at the Mayo Clinic, Johns Hopkins University, and scientist positions in the Bristol-Myers Squibb Co. before joining Yale University. He is a member of the National Academy of Sciences, the National Academy of Medicine, and a Fellow of the American Association for Cancer Research (AACR).

Dr. Halene is a physician-scientist who received her MD degree at Eberhardt-Karls-University in Tübingen, Germany. She subsequently completed a postdoctoral fellowship in the laboratory of Donald B. Kohn at CHLA in Los Angeles and her residency in internal medicine in the traditional program at Yale New Haven Hospital. She completed her fellowship in hematology/oncology at Yale and joined the ladder faculty at YSM as an assistant professor in 2010. At that time she was also named director of the Hematology Tissue Bank for Yale Cancer Center. She was promoted to associate professor in 2016 and subsequently served as interim chief of the Section of Hematology prior to her appointment as chief of that section in 2020. Her laboratory studies hematopoiesis and myelopoiesis and in particular how mutations in splicing factors and perturbations in RNA modifications contribute to hematologic malignancies such as myelodysplasia and leukemia. Dr. Halene, in collaboration with the Flavell laboratory in the YSM Department of Immunobiology, has developed the first efficient xenotransplantation model in humanized mice to study myelodysplasia and enable testing of novel drug treatments. Dr. Halene’s research has garnered significant attention from the international community, as evidenced by numerous invited speaking engagements, an invitation to serve as a section editor on myeloid malignancies for a major journal, and publications in top tier journals in her field. In 2015 she was presented with the Sir William Osler Young Investigator Award and in 2019 was elected a member of the Interurban Clinical Club. Dr. Halene is director of the DeLuca Center for Innovation in Hematology Research. Through generous funding from The Frederick A. DeLuca Foundation, the center has established a comprehensive biospecimen bank, awarded pilot and career development grant funding to advance cutting-edge discoveries in hematologic malignancies and classical hematologic disorders. Meet Dr. Stephanie Halene>>

Dr. Alfred Ian Lee is Professor of Medicine (Hematology) and Program Director for the hematology/oncology fellowship program. He received his MD/PhD from the Yale School of Medicine in 2004. Dr. Lee completed residency in internal medicine at Brigham & Women’s Hospital, where he served as Chief Medical Resident, followed by a fellowship in hematology/oncology at Dana-Farber Cancer Institute. His primary academic interests are classical hematology, thrombosis, and medical education. He has received such honors as the Charles W. Bohmfalk Prize for teaching in the basic sciences, the Leah M. Lowenstein Award for excellence in the promotion of humane and egalitarian medical education, the Yale Cancer Center Award for Mentorship Excellence, and the David J. Lefell Prize for Clinical Excellence.

Hometown: Kingsville, TX Medical School: University of California San Francisco Undergraduate: Harvard College Professional Interests: Surgical oncology, Cancer research, Health disparities, Health economics, Medical device/diagnostics. Hobbies: Traveling abroad with my wife Shirley and son Oliver, Ballroom dancing, Running, Basketball